Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

Christian Buske, Meletios A Dimopoulos, Alexander Grunenberg, Efstathios Kastritis, Cécile Tomowiak, Beatrice Mahé, Xavier Troussard, Roman Hájek, Andreas Viardot, Olivier Tournilhac, Thérèse Aurran, Stéphane Leprêtre, Hacène Zerazhi, Bénédicte Hivert, Véronique Leblond, Sophie de Guibert, Lena Brandefors, Ramón García‐Sánz, María Gomes da Silva, Eva Kimby, Birgit Schmelzle, Dajana Kaszynski, Jens Dreyhaupt, Rainer Muche, Pierre Morel (2023). Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. , 41(14), DOI: https://doi.org/10.1200/jco.22.01805.